Very significant PR, including:
1) dosage of Kevetrin increasing, thus no DLT yet and trial is continuing on the way toward discovering MTD
2) clearly stated intention to go for "breakthrough therapy" designation with FDA at the end of Kevetrin P1 trial
3) Dr. Reddy is now formulating Prurisol in a "further condensed process... delivering much higher yields," suggesting that manufacturing "in quantity" appears doable (more efficiently and inexpensively)
4) POC trial for Prurisol on track for Q2 in Europe
5) "Quiet period" has ended and thus additional updates will be forthcoming (might this also be sending a message to a couple MMs?)
6) (my personal favorite) the first P21 data report is expected by mid-March, suggesting this data will be published soon after. Positive P21 data could be the rocket-launcher.
very impressive PR, IMO
Market Data 
Markets 
AI
